Drainobag真空负压引流瓶在乳腺癌根治术后的应用

目的:探讨Drаinobag真空负压引流瓶在乳腺癌根治术后的应用效果。方法:对185例在我科施行乳腺癌改良根治术的患者,术后随机分为两组,对照组(92例)选择持续电动负压吸引引流,实验组(93例)应用Drainobag真空负压引流瓶引流,对两组术后总引流量、置管时间、皮下积液、皮瓣坏死和术后住院时间进行比较。结果:实验组术后总引流量、置管时间、皮下积液、皮瓣坏死率和术后住院时间均明显低于对照组(P<0.05)。结论:应用Drainobag真空负压引流瓶引流效果好,能有效预防术后并发症的发生,缩短了住院时间,减少了医疗费用。     

Drainobag真空高负压引流瓶在老年乳腺癌术后引流中的应用研究

目的对老年人乳腺癌术后Drainobag真空高负压引流技术的治疗效果进行研究。方法将2009年3月至2013年12月收治乳腺癌改良根治术120例,随机分为实验组和对照组。实验组65例,应用Drainobag真空高负压引流技术进行引流。对照组55例,使用传统负压引流瓶引流。分析两组术后皮下积液、皮瓣缺血坏死和并发症情况。结果实验组皮下积液与皮瓣坏死发生率均显著低于对照组,差异有统计学意义(P0.05)。实验组轻度皮肤损伤的发生率低于对照组,差异有统计学意义(P0.05)。结论改良乳腺癌根治术后应用Drainobag真空高负压引流技术可减少皮下积液和皮瓣缺血坏死的发生。     

不同引流及加压方式对乳腺癌术后的影响

[摘要] 目的：探讨不同负压引流及加压包扎方式在乳腺癌术后的效果。方法：将95例在我科实行乳腺癌改良根治术的患者分为三组。A组：腋下置一根负压引流管,B组：腋下和胸骨旁分别置一根负压引流管,A组与B组术后均加压包扎,C组：置管方法同B组不加压包扎,比较三组术后24h、48h、72h的总引流量;带管时间;切口感染、皮下积液及皮瓣坏死发生情况。结果：A组术后总引流量少于B组,带管时间短于B组（P<0.05）;两组皮下积液及皮瓣坏死发生无差异（P>0.05）。B组术后总引流量少于C组,带管时间短于C组,皮下积液发生低于C组（P<0.05）。结论：乳腺癌术后单管负压引流联合加压包扎能减少创面引流量,减少带管数目,缩短带管时间,但不增加切口感染、皮下积液及皮瓣坏死发生,可用于临床推广。     

高负压引流技术在乳腺癌改良根治术中的应用

目的探讨高负压引流技术在乳腺癌根治术中的应用价值。方法选取2011年5月至12月肇庆市第一人民医院拟行乳腺癌改良根治术的乳腺癌患者100例,随机抽取50例采用高负压引流系统引流,称为高负压引流组,另50例采用传统低负压引流球引流,称为低负压引流组。将两组间的拔管时间、住院时间、引流量、皮瓣坏死率、皮下积液及术后恢复期的生活质量等指标进行对比分析。结果两组在拔管时间、住院时间、引流量、皮瓣坏死及皮下积液等方面比较差异无统计学意义,术后恢复期的生活质量高负压引流组有明显改善。结论引流方式不能减少乳腺癌改良根治术患者术后并发症;高负压引流可显著改善乳腺癌根治术患者术后恢复期的生活质量,也能减少医生的工作量,具有临床推广价值。     

乳腺癌改良根治术后两种引流装置引流效果的比较研究

目的 研究一次性负压引流器和一次性高真空负压引流瓶两种不同引流装置在乳腺癌改良根治术中的医疗和护理应用价值.方法 选择乳腺癌手术后引流患者60例,传统组30例应用一次性负压引流器,改进组30例应用一次性高真空负压引流瓶,比较两种引流效果.结果 改进组术后使用止痛剂人数少于传统组,术后72 h引流量高于传统组,皮下积液发生率低,术后拔除引流管时间、术后拆线时间、术后出院时间提前,差异均有统计学意义(P＜0.05).结论 一次性高真空负压引流瓶与一次性负压引流器相比较,能够降低皮下积液发生率,减少患者带管时间,使患者舒适感增加;缩短住院天数;使患者使用更安全、放心;护士操作省时、简便.     

乳腺癌改良根治术后两种引流装置引流效果的比较研究

目的研究一次性负压引流器和一次性高真空负压引流瓶两种不同引流装置在乳腺癌改良根治术中的医疗和护理应用价值。方法选择乳腺癌手术后引流患者60例,传统组30例应用一次性负压引流器,改进组30例应用一次性高真空负压引流瓶,比较两种引流效果。结果改进组术后使用止痛剂人数少于传统组,术后72h引流量高于传统组,皮下积液发生率低,术后拔除引流管时间、术后拆线时间、术后出院时间提前,差异均有统计学意义（P〈0．05）。结论一次性高真空负压引流瓶与一次性负压引流器相比较,能够降低皮下积液发生率,减少患者带管时间,使患者舒适感增加;缩短住院天数;使患者使用更安全、放心;护士操作省时、简便。     

不同引流及加压方式对乳腺癌患者术后恢复的影响

目的:探讨不同负压引流及加压包扎方式对乳腺癌患者术后恢复的影响。方法:选取2015年1月～2018年12月收治的95例行乳腺癌改良根治术乳腺癌患者为研究对象,根据负压引流及加压包扎方式不同将患者分为三组,A组28例,B组37例,C组30例。A组腋下置一根负压引流管,B组腋下和胸骨旁分别置一根负压引流管,两组术后均加压包扎;C组置管方法同B组不加压包扎。比较三组术后24 h、48 h、72 h引流量,带管时间,切口感染、皮下积液及皮瓣坏死发生情况。结果:A组术后24 h、48 h、72 h引流量少于B组,带管时间短于B组(P0.05),两组皮下积液及皮瓣坏死并发症发生率比较无显著性差异(P0.05);B组术后24 h、48 h、72 h引流量少于C组,带管时间短于C组,皮下积液发生率低于C组(P0.05)。结论:乳腺癌患者术后单管负压引流联合加压包扎能减少创面引流量,减少带管数目,缩短带管时间,且不会增加切口感染、皮下积液及皮瓣坏死发生率。     

环状负压引流加多点皮瓣固定预防乳腺癌术后皮下积液效果观察

目的探究环状负压引流联合多点皮瓣固定预防乳腺癌术后皮下积液的效果。方法将收治的40例拟行乳腺癌改良根治术的患者采用随机数字表法分为观察组(环状负压引流+多点皮瓣固定)与对照组(单管负压引流+弹性加压包扎)各20例,观察两组术后皮下积液发生率、术后引流情况与近期疗效。结果术后观察组、对照组发生皮下积液率分别为5%和30%(P<0.05);观察组术后1、2、3d引流量均显著低于对照组(P<0.05);观察组胸壁拔管时间、腋窝置管时间、住院时间均显著短于对照组(P<0.05)。结论乳腺癌改良根治术可通过多点皮瓣固定术与环状负压引流减少术后皮下积液发生率,改善引流情况,有效缩短住院时间,值得临床推广。     

乳腺癌术后两种负压引流方法的临床效果观察及护理

目的：观察乳腺癌根治术后中心负压引流和一次性负压引流器引流，在预防乳腺癌术后皮下积液和皮瓣坏死中的临床效果及护理要点。方法：将我科行乳腺癌改良根治术的60例病人随机分为对照组和实验组，对照组术后应用中心负压引流，实验组术后应用一次性负压引流器引流，观察两组皮下积液、皮瓣坏死发生率。结果：两组对照，实验组皮下积液：皮瓣坏死发生率明显低于对照组（P〈0．05）。结论：预防乳腺癌术后皮下积液、皮瓣坏死的发生，一次性负压引流器引流优于中心负压引流。     

胶原蛋白海绵在乳腺癌改良根治术中的应用效果观察

目的探讨胶原蛋白海绵在乳腺癌改良根治术中应用的价值。方法将156例乳腺癌患者随机分成两组,对照组术后常规采取加压包扎持续负压引流,实验组则联合使用胶原蛋白海绵,分别观察两组置管时间、皮下积液和皮瓣坏死的发生率。结果实验组的置管时间(4.8±1.3)d明显短于对照组(6.3±2.7)d,有显著性差异(P<0.01),实验组皮下积液和皮瓣坏死的发生率分别为1.3%和2.6%,明显少于对照组的10.3%和11.5%,有显著性差异(P<0.05)。结论在乳腺癌改良根治术后引流管持续负压引流联合应用胶原蛋白海绵可缩短置管时间,减少皮下积液和皮瓣坏死的发生率。     

A COMPARISON OF PHENYLPROPANOL (0.5%) WITH CHLOROFORM (0.25%) AND AN ADMIXTURE OF METHYL HYDROXYBENZOATE (0.06%) AND PROPYL HYDROXYBENZOATE (0.03%) AS PRESERVATIVES IN LIQUID MEDICINES

The effectiveness as a preservative in liquid medicines of phenylpropanol 0.5%, chloroform 0.25% and an admixture of methyl hydroxybenzoate 0.06% with propyl hydroxybenzoate 0.03% has been evaluated by determination of sterilization times. Phenylpropanol was as effective as chloroform against Escherichia coli and Staphylococcus aureus ; in some mixtures phenylpropanol was more rapidly bactericidal than was chloroform against Pseudomonas aeruginosa. The admixture of hydroxybenzoates was a poor preservative. Problems in the preservation of paediatric chalk mixture were solved by the use of sterilized chalk and the replacement of tragacanth by derivatives of starch.     

Alitretinoin (Panretin) gel 0.1%.

This review focuses on the use of alitretinoin (Panretin) gel 0.1% therapy as a new topical treatment of cutaneous lesions in patients with AIDS-related Kaposi's sarcoma.     

Treatment of hyperthermia-induced extravasation with hypertonic saline (7.5%) in 6% dextran 70 (HSD) in Wistar/Furth rats.

This study determined the effectiveness of hypertonic saline (7.5%) in 6% Dextran 70 (HSD) in reducing hyperthermia-induced extravasation in Wistar/Furth (WF) rats and compared this extravasation with that previously reported in Sprague-Dawley (SD) rats. Wistar/Furth rats (male, n = 12/group, 300-325 g) were placed unrestrained in a chamber (41.5 degrees C) until a core temperature (Tc) of 42.6 degrees C was attained. Immediately following heat exposure, HSD or normal saline (4 mL/kg) was administered via jugular catheter, followed 15 min later by Evan's blue (Eb, 25 mg/kg) in normal saline. After another 15-min interval, animals were anesthetized, exsanguinated, tissues removed and washed in normal saline, and Eb was extracted with formamide. Another group of normothermic WF rats were also given Eb and had tissues harvested. Comparisons were made to extravasation in normothermic and hyperthermic SD rats. In hyperthermic SD rats, Eb content increased significantly in liver, kidney, and intestinal tissues. In hyperthermic WF rats compared to normothermic WF rats, Eb content of kidney and spleen was increased; however, Eb content of heart, skeletal muscle, and intestine was significantly decreased. HSD-treated WF rats had increased extravasation in intestinal tissue compared to that of saline-treated rats. However, HSD treatment resulted in significant decreases in wet weight/dry weight ratios of heart (4.34 +/- 0.10 versus 4.51 +/- 0.11) and skeletal muscle tissue (3.78 +/- 0.08 versus 3.91 +/- 0.08). Findings of this study indicate that HSD did not prevent the hyperthermia-induced extravasation of Eb in kidney and spleen; that the increase in plasma volume following HSD administration is most likely due to the movement of fluid into the vasculature from the skeletal muscle mass; and that the WF strain may have limited value for the study of extravasation.     

Hydrocortisone 17-butyrate (Locoid) 0.1% cream versus hydrocortisone (Uniderm) 1% cream in the treatment of children suffering from atopic dermatitis

A randomized, double-blind, left-right study to compare the therapeutic efficacy of hydrocortisone 17-butyrate (Locoid) 0.1% cream with hydrocortisone (Uniderm) 1% cream was performed in forty children suffering from atopic dermatitis. The medications were applied to symmetrical bilateral skin lesions twice daily for a maximum of 4 weeks or until complete clinical clearance of such lesions had occurred. Complete clearance of skin symptoms was found in 36% of the Locoid-treated sides and in 23% of the Uniderm-treated sides following 2 weeks of therapy and in 60% and 30%, respectively, after 4 weeks of treatment. This difference in clearance rate after 4 weeks between both preparations was significantly in favour of Locoid cream. The expressed preferences of patients/parents and investigator were also significantly in favour of Locoid cream, both after 2 and 4 weeks. No serious side-effects were reported during this study. It is concluded that Locoid cream is significantly superior to Uniderm cream in the treatment of atopic dermatitis in children.     

Gelnique (oxybutynin chloride) 10% gel for overactive bladder

This article provides an overview of oxybutynin transdermal gel (Gelnique), its uses, and product information.     

5% Dimethyl sulfoxide (DMSO) and pentastarch improves cryopreservation of cord blood cells over 10% DMSO

BACKGROUND: Cell number and viability are important in cord blood (CB) transplantation. While 10% dimethyl sulfoxide (DMSO) is the standard medium, adding a starch to freezing medium is increasingly utilized as a cytoprotectant for the thawing process. Similar to hetastarch, pentastarch has the advantages of faster renal clearance and less effect on the coagulation system. STUDY DESIGN AND METHODS: We compared a lower DMSO concentration (5%) containing pentastarch with 10% DMSO and performed cell viability assay, colony‐forming units (CFUs), and transplantation of CB cells in NOD/SCID IL2Rγ^null mice. RESULTS: CB cells in 5% DMSO/pentastarch had similar CD34+, CD3+, and CD19+ cell percentages after thawing as fresh CB cells. CB cells in 5% DMSO/pentastarch had higher viability (83.3 ± 9.23%) than those frozen in 10% DMSO (75.3 ± 11.0%, p < 0.05). We monitored cell viability postthaw every 30 minutes. The mean loss in the first 30 minutes was less in the 5% DMSO/pentastarch group. At the end of 3 hours, the viability decreased by a mean of 7.75% for the 5% DMSO/pentastarch and 17.5% for the 10% DMSO groups. CFUs were similar between the two cryopreserved groups. Frozen CB cells engrafted equally well in IL2Rγ^null mice compared to fresh CB cells up to 24 weeks, and CB cells frozen in 5% DMSO/pentastarch engrafted better than those in 10% DMSO. CONCLUSION: Our data indicate that the lower DMSO concentration with pentastarch represents an improvement in the CB cryopreservation process and could have wider clinical application as an alternate freezing medium over 10% DMSO.     

Hydrocortisone 17-butyrate (Locoid) 0.1% fatty cream versus desonide (Apolar) 0.1% ointment in the treatment of patients suffering from atopic dermatitis

A randomized, double-blind, left-right study to compare the therapeutic efficacy and the cosmetic acceptability of the new hydrocortisone 17-butyrate (Locoid) 0.1% fatty cream application form with desonide (Apolar) 0.1% ointment was performed in thirty patients suffering from moderate to severe atopic dermatitis. The medications were applied to symmetrical, bilateral skin lesions twice daily for 4 weeks. Both treatments effected highly significant reductions of the score values for the severity of all clinical skin parameters assessed. Score reductions were, however, more pronounced on Locoid-treated sides than on Apolar-treated sides both after 2 and 4 weeks of therapy. It appeared further that clinical efficacy of treatment at completion of the study was also in favour of Locoid-treated sides, indicating that Locoid fatty cream is more effective than Apolar ointment. No serious side-effects were reported during the study. The expressed patient preferences with respect to cosmetic acceptability of treatments were significantly in favour of Locoid fatty cream, indicating that patients preferred the use of this new galenic formulation over an ointment formulation. It is concluded that the new application form of Locoid, a fatty cream, is a useful and beneficial addition to topical corticosteroid therapy, which will promote patient compliance in a wide range of corticosteroid-responsive skin diseases.